GLN 1062

Drug Profile

GLN 1062

Alternative Names: Galantamine pro-drug - Galantos Pharma; GLN-1062; Memogain; Pro-galantamine - Galantos Pharma

Latest Information Update: 10 May 2016

Price : $50

At a glance

  • Originator Galantos Pharma
  • Developer Galantos Pharma; Neurodyn
  • Class Alkaloids; Benzazepines; Nootropics; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; Nicotinic receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 05 Mar 2016 Phase-I clinical trials in Alzheimer's disease (In volunteers) in Netherlands (Intranasal) (NTR5678)
  • 09 Sep 2014 Phase-I clinical trials in Alzheimer's disease (In volunteers) in Canada prior to September 2014 (Intranasal)
  • 09 Sep 2014 Efficacy, adverse events and pharmacokinetics data from a phase Ia trial in Alzheimer's disease (in volunteers) released by Neurodyn
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top